Last reviewed · How we verify
Strattera
Strattera, marketed by the University of Oklahoma, is a non-stimulant medication for attention deficit hyperactivity disorder (ADHD). Its key strength lies in its unique mechanism of action, distinguishing it from stimulant-based competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Strattera |
|---|---|
| Also known as | atomoxetine HCL, atomoxetine |
| Sponsor | University of Oklahoma |
| Target | Krueppel-like factor 10, Kir3.1/Kir3.4, Kir3.1/Kir3.2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Attention deficit hyperactivity disorder
Common side effects
- Nausea
- Vomiting
- Fatigue
- Decreased appetite
- Abdominal pain
- Somnolence
- Blood pressure increased
- Early morning awakening (terminal insomnia)
- Flushing
- Mydriasis
- Sinus tachycardia
- Asthenia
Serious adverse events
- Seizures
- Seizures (poor metabolizers)
Key clinical trials
- Atomoxetine and DAW2022 on OSA Severity (PHASE1, PHASE2)
- Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (PHASE3)
- Atomoxetine and Executive Function in PTSD (PHASE4)
- TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (EARLY_PHASE1)
- A Novel Pharmacological Therapy for Obstructive Sleep Apnea (PHASE2)
- Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea (PHASE1, PHASE2)
- Endotype DIrected Treatment for OSA in Down Syndrome (PHASE4)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Strattera CI brief — competitive landscape report
- Strattera updates RSS · CI watch RSS
- University of Oklahoma portfolio CI